Investors are beginning to turn cautious on biotechnology stocks as a rapid rise in Treasury yields dents the appeal for shares of companies that are often viewed as risky all-or-nothing bets on breakthrough medical treatments.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.